Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells by Delgado-Maroto, Virginia et al.
Cortistatin reduces atherosclerosis
in hyperlipidemic ApoE-deficient
mice and the formation of foam cells
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Delgado-Maroto, V., R. Benitez, I. Forte-Lago, M. Morell, E.
Maganto-Garcia, L. Souza-Moreira, F. O’Valle, et al. 2017.
“Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-
deficient mice and the formation of foam cells.” Scientific Reports
7 (1): 46444. doi:10.1038/srep46444. http://dx.doi.org/10.1038/
srep46444.
Published Version doi:10.1038/srep46444
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630618
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
1Scientific RepoRts | 7:46444 | DOI: 10.1038/srep46444
www.nature.com/scientificreports
Cortistatin reduces atherosclerosis 
in hyperlipidemic ApoE-deficient 
mice and the formation of foam 
cells
Virginia Delgado-Maroto1, Raquel Benitez1, Irene Forte-Lago1, Maria Morell1, 
Elena Maganto-Garcia2, Luciana Souza-Moreira1, Francisco O’Valle3, Mario Duran-Prado1,4, 
Andrew H. Lichtman2, Elena Gonzalez-Rey1 & Mario Delgado1
Atherosclerosis is a chronic inflammatory cardiovascular disease that is responsible of high mortality 
worldwide. Evidence indicates that maladaptive autoimmune responses in the arterial wall play critical 
roles in the process of atherosclerosis. Cortistatin is a neuropeptide expressed in the vascular system 
and atherosclerotic plaques that regulates vascular calcification and neointimal formation, and inhibits 
inflammation in different experimental models of autoimmune diseases. Its role in inflammatory 
cardiovascular disorders is largely unexplored. The aim of this study is to investigate the potential 
therapeutic effects of cortistatin in two well-established preclinical models of atherosclerosis, and 
the molecular and cellular mechanisms involved. Systemic treatment with cortistatin reduced the 
number and size of atherosclerotic plaques in carotid artery, heart, aortic arch and aorta in acute and 
chronic atherosclerosis induced in apolipoprotein E-deficient mice fed a high-lipid diet. This effect was 
exerted at multiple levels. Cortistatin reduced Th1/Th17-driven inflammatory responses and increased 
regulatory T cells in atherosclerotic arteries and lymphoid organs. Moreover, cortistatin reduced the 
capacity of endothelial cells to bind and recruit immune cells to the plaque and impaired the formation 
of foam cells by enhancing cholesterol efflux from macrophages. Cortistatin emerges as a new 
candidate for the treatment of the clinical manifestations of atherosclerosis.
Cardiovascular disease has become the most frequent cause of death globally. Although many diseases affect the 
cardiovascular system, myocardial infarction and ischemic stroke caused by atherosclerosis dominate mortality 
and morbidity statistics worldwide. Far to the traditional view of atherosclerosis resulting from a passive build up 
of cholesterol in the artery wall, there is now much evidence that chronic inflammation and autoimmune mecha-
nisms are critically involved in its pathogenesis, especially during progression phase and during the onset of vul-
nerable plaques, as reflected by the large number of monocyte-derived macrophages and T lymphocytes within 
the atherosclerotic plaque1–3. These findings raise the possibility that immunomodulatory therapeutic approaches 
may be successful in this cardiovascular disease, alone or in addition to lipid-lowering therapy.
Cortistatin is a neuropeptide initially discovered in brain cortex and hypothalamus based in its inhibitory 
neuronal activities4 that recently emerged as a pleiotropic immunomodulatory factor5. Due to its remarkable 
sequential/structural resemblances with somatostatin, cortistatin exerts many somatostatin-like functions, espe-
cially concerning hormonal and neuronal regulation6,7. However, cortistatin plays unique functions in brain and 
immune system4–8, which are related to its capacity to bind to receptors other than those somatostatin, mainly 
the ghrelin-receptor7,9,10. Although its role in the cardiovascular system is largely unknown, recent evidence 
invites to the study of the effect of cortistatin in inflammatory cardiovascular diseases. First, the cardiovascu-
lar system produces cortistatin, especially in response to injury. Thus, heart, arterial endothelium and arterial 
smooth muscle cells (SMCs) express cortistatin and its receptors10–12. Moreover, cortistatin is expressed in human 
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atherosclerotic plaques, specifically in SMCs and infiltrating inflammatory cells and its expression increases in 
complex plaques11. Cortistatin expression also augmented in mouse arteries subjected to blood-flow alterations, 
in plasma of patients with coronary artery lesions and in hearts of mice with autoimmune myocarditis11,13,14. 
Second, treatment with cortistatin improves vasculopathies associated with vascular remodelling and reduces 
experimental arterial stenosis and vascular calcification11,15. In agreement, cortistatin-deficient mice responded 
to neointimal lesion with exacerbated vascular responses11. Finally, cortistatin regulates both innate and adap-
tive immune responses in many inflammatory and autoimmune disorders, including experimental autoimmune 
myocarditis, collagen-induced arthritis, experimental autoimmune encephalomyelitis and inflammatory bowel 
disease8,14,16–18.
Therefore, here we investigated the effect of cortistatin in two experimental models of acute and chronic 
atherosclerosis induced in apolipoprotein E-deficient (apoE−/−) mice fed a high-lipid Western diet, as well as the 
potential cellular and molecular mechanisms involved.
Results
Cortistatin protects from atherosclerosis in partially ligated carotid artery of hyperlipidemic 
mice by impairing Th1/Th17-driven inflammatory responses. We investigated the potential 
therapeutic effect of cortistatin in two models of atherosclerosis in genetically susceptible apoE−/− mice fed a 
high-lipid diet. In the first model, we ligated three of the four caudal branches of the left common carotid artery 
(Supplementary Fig. S1A) and then fed animals with a Western diet for 3 weeks. This partial ligation causes 
disturbed blood-flow with low and oscillatory shear stress and accelerated atherosclerosis in the carotid artery 
of hyperlipidemic mice19. In comparison to contralateral unligated artery, ligated carotid developed severe ath-
erosclerotic plaques that progressively occupied the vascular lumen (Fig. 1A and B, Supplementary Fig. S1). 
The plaques were characterized by the predominant presence of cells stained with Oil Red O, a marker of lipid 
accumulation, probably corresponding to lipid-loaded macrophages (Fig. 1A). Studies of immunofluorescence 
confirmed the presence of infiltrating CD68+ macrophages, as well as of CD4+ T cells and α -actin+ SMCs, in 
the carotid plaques (Fig. 1C). Moreover, in comparison to unligated carotid, ligated carotid showed increased 
gene expression of the macrophage markers CD68 and F4/80 (assayed by qPCR, Fig. 1D), and higher presence 
of CD45+ leukocytes, including CD11b+ macrophages and CD4 T lymphocytes (analyzed by flow cytometry, 
Fig. 1E). Systemic administration of cortistatin three times per week, during two weeks resulted in a strong 
reduction in the formation of atherosclerotic plaques in the ligated carotid (Fig. 1A, Supplementary Fig. S1). 
Moreover, cortistatin treatment decreased the presence of macrophages, CD4 T cells and SMCs in the plaque 
(Fig. 1C and D). Interestingly, cortistatin also impaired the increase observed in carotid medial layer area, which 
is a consequence of vascular remodelling that occurs after artery ligation (Fig. 1B, Supplementary Fig. S1).
Because atherogenic Th1 and Th17 cells play a major role in development and progression of the athero-
sclerotic plaque1,2, we evaluated the effect of cortistatin treatment in the presence of these pathogenic cells in 
plaques and in lymphoid organs. As expected, flow cytometric analysis of single-cell isolates of ligated carotid 
of untreated mice showed that plaque-infiltrating CD4 T cells mainly included IFNγ -producing Th1 cells, and 
some IL-17-producing Th17 cells (Fig. 2A). Determination of cytokine contents in protein extracts of ligated 
carotids bearing atherosclerotic plaques confirmed the increased expression of inflammatory cytokines linked 
to development of atherosclerosis20, including TNFα and IFNγ (Fig. 2B). Moreover, ex vivo activation of ligated 
carotid resulted in high secretion of IFNγ and IL-17 (Supplementary Fig. S2A). In contrast, arteries isolated from 
hyperlipidemic mice that were treated with cortistatin showed low numbers of IFNγ - and IL-17-producing CD4 
T cells (Fig. 2A) and produced low levels of inflammatory cytokines (Fig. 2B, Supplementary Fig. S2A). Moreover, 
the addition of cortistatin to cultures of ligated carotid arteries diminished the production of TNFα and IFNγ , 
suggesting a direct suppressive effect of the neuropeptide in atherosclerotic plaques (Fig. 2C).
On the other hand, we observed that the number of total cells in draining lymph nodes (DLNs) of the ligated 
carotid increased with respect to the corresponding DLNs isolated in the contralateral side of the same ani-
mal (DLNs of the unligated artery) or DLNs of naïve apoE−/− mice fed a normal chow diet (Fig. 2D), or with 
respect to spleen or mesenteric lymph nodes (non-DLNs) of apoE−/− mice fed a Western diet during 3 weeks 
(Supplementary Fig. S2B), pointing out to a major immune response occurring in DLNs of ligated carotids. 
Analysis of IFNγ - and IL-17-producing CD4 cells by flow cytometry indicated a moderate increase in these 
atherogenic T cell populations in DLNs of ligated carotid, but not in contralateral DLNs or in spleen (Fig. 2D, 
Supplementary Fig. S2C–E). Treatment with cortistatin decreased the numbers of total cells in DLNs, especially 
of both Th1 and Th17 cells (Fig. 2D and E, Supplementary Fig. S2B–E). In contrast, the percentage of FoxP3+ 
regulatory T cells (Treg) in the CD4 population of DLNs significantly increased (p = 0.02) with cortistatin treat-
ment 14 days after ligation (Fig. 2F), which correlated with an elevation of this cell population in the ligated 
carotid artery (Fig. 2G). Although cortistatin did not significantly affect the percentage of Treg cells in DLNs at 
later time points (3 weeks after ligation, Fig. 2F), it restored the ratios between Th1 cells and Treg (Th1/Treg ratio 
of 0.5 for naïve apoE−/− mice, Th1/Treg ratio of 1.8 for untreated atherosclerotic mice and Th1/Treg ratio of 0.6 
for cortistatin-treated atherosclerotic mice). Therefore, these findings indicate that treatment with cortistatin 
protects from acute atherosclerosis in carotid artery and impairs Th1 and Th17-driven inflammatory responses 
at the vessels and DLNs.
Cortistatin decreases the formation of plaques in a model of chronic atherosclerosis. Next, we 
investigated potential protective effects of cortistatin in a model of chronic atherosclerosis in apoE−/− mice fed a 
high-lipid Western diet for 16 weeks. Systemic treatment with cortistatin, 3 times per week, reduced the number 
and size of atherosclerotic lesions in descending aorta, aortic sinus and aortic arch (Fig. 3A–C). Remarkably, 55% 
and 35% of cortistatin-treated mice did not show evidence of plaque formation in the descending aorta and aortic 
sinus, respectively, at the end of treatment. Atherosclerotic animals treated with cortistatin showed plaques in 
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Figure 1. Cortistatin protects from acute atherosclerosis in carotid artery in hyperlipidemic mice. ApoE−/− 
mice subjected to partial ligation of left carotid artery and fed a high-fat diet were intraperitoneally treated with 
PBS (control) or with cortistatin (CST) every other day starting one day after ligation. Contralateral unligated 
carotid and ligated carotid were collected two and three weeks after ligation. (A) The volume of atherosclerotic 
lesions was determined by morphometry in carotid sections isolated 3 weeks after ligation. Images correspond 
to Oil red O-stained cryosections obtained at 0.5 or 1.5 mm proximal to carotid bifurcation. Each symbol 
in right panel represents 1 mouse, and horizontal lines correspond to the mean value of each experimental 
group. (B) Areas of intimal lesions and media layers were measured by morphometry in sections stained with 
hematoxylin-eosin or Oil red O. Supplementary Fig. S1 shows intima/media ratio values. n = 14 mice per group, 
performed in three experiments. (C) Immunofluorescence analysis of CD68+ macrophages, smooth muscle 
α -actin+ (SMA) cells and CD4+ lymphocytes in carotid sections isolated 3 weeks after ligation. Nuclei were 
DAPI-counterstained. Supplementary Fig. S1 shows immunostaining negative controls. n = 6 mice per group, 
performed in two experiments. (D) The presence of macrophages was confirmed by qPCR analysis of CD68 and 
F4/80 mRNA expression in carotids isolated 3 weeks after ligation. n = 4 mice per group, pooled in two samples. 
(E) Flow cytometric analysis of cell infiltrates isolated from carotids 3 weeks after ligation. The percentages 
of CD45+ leukocytes in whole carotid cell isolates, and of CD11b+ monocytes and CD4+ lymphocytes in 
gated CD45+ cells were determined. The numbers of total CD45+, CD11b+ and CD4+ cells per carotid artery 
are shown. n = 6 mice per group, performed in two experiments. Scale bars: 100 μ m. *p < 0.05, **p < 0.001, 
***p < 0.0001 vs control.
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aortic sinus and aortic arch with lower numbers of leukocytes in general, and of macrophages and CD4 T cells 
in particular (Fig. 3B–D). Moreover, treatment with cortistatin reduced the presence of α -actin+ SMCs in the 
plaques of aortic arch and sinus (Fig. 3B and C) and diminished the medial muscle layer thickening in aortic arch 
(Supplementary Fig. S3).
Regarding the mechanisms involved in the protective effect of cortistatin in chronic atherosclerosis, we found 
that cortistatin treatment did not significantly change the plasma cholesterol concentrations in atherosclerotic 
mice (Supplementary Fig. S4). Other parameters including food intake, body weight or glucose levels were not 
affected by cortistatin treatment (Supplementary Fig. S4). As expected, aortic plaques of apoE−/− mice fed a 
Figure 2. Cortistatin downregulates local and peripheral inflammatory and T-cell responses in acute 
atherosclerosis. ApoE−/− mice subjected to partial ligation of left carotid artery and fed a high-fat diet were 
treated with PBS (control) or with cortistatin (CST) every two days, starting one day after ligation. (A) The 
presence of IL17- and IFNγ -producing T cells in carotids was determined by flow cytometric analysis of cells 
isolated from carotids obtained 3 weeks after ligation. Plots correspond to intracellular cytokine staining in 
gated CD4+ cells. n = 6 mice per group. (B) Cytokine levels were determined in protein extracts isolated from 
carotid arteries 3 weeks after ligation and expressed as ng of cytokine per mg of protein. n = 5 mice per group. 
(C) Cytokine production by ligated carotids isolated from untreated control mice 3 weeks after ligation and 
ex vivo activated in the absence (none) or presence of cortistatin. n = 6 mice per group, performed in two 
independent experiments. **p < 0.0001 vs control. (D) Total number of cells in draining lymph nodes (DLNs) 
of ligated carotid and of contralateral unligated carotid isolated 2 weeks after ligation. Naïve apoE−/− mice fed 
a normal chow diet were used as reference. Supplementary Fig. S2 shows values determined in non-draining 
mesenteric lymph nodes and spleen. n = 5 mice per group. (E) Number and percentages of IFNγ -producing 
CD4 T cells and IL-17-producing CD4 T cells in DLNs of ligated and unligated carotid arteries isolated 2 weeks 
after ligation were determined by flow cytometric analysis. n = 5 mice per group. Supplementary Fig. S2 shows 
values obtained in DLNs and spleens isolated 3 weeks after ligation and the percentage of CD4+ cells in DLNs 
and spleens. (F) Flow cytometric analysis of FoxP3+ cells in gated CD4+ lymphocytes of DLNs of unligated 
and ligated carotid arteries. n = 5 mice per group. (G) Percentage of CD25+ FoxP3+ cells in gated CD4+ 
lymphocytes determined by flow cytometry in cell suspensions isolated from ligated carotids 3 weeks after 
ligation. n = 6 mice per group. *p < 0.05; **p < 0.001; ***p < 0.0001 vs control.
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Figure 3. Cortistatin protects from hyperlipidemic diet-induced chronic atherosclerosis. ApoE−/− mice fed 
a high-fat diet during 16 weeks were intraperitoneally treated with PBS (control) or cortistatin (CST) three times 
per week, starting one week after initiation of diet. (A) Images of descending aorta stained with Sudan IV and 
quantification of percentage of aorta area occupied by plaque. Each symbol corresponds to 1 mouse. Horizontal 
lines are the mean and vertical lines represent s.e.m. for each experimental group. (B) Images of longitudinal 
sections of aortic arch stained with Oil Red O and quantification of atherosclerotic lesion area. Scale bars: 500 μ m.  
Images and quantification of cross-sections of aortic arch are shown in Supplementary Fig. S3. (C) Images of 
sections of aortic arch immunostained for infiltrating CD68+ macrophages and CD4+ T cells and for α SMA+ 
smooth muscle cells. Quantification of positive areas for each cell type is shown (n = 6 mice/group). Scale bars: 
100 μ m. (D) Images of sections of aortic root sinus stained with Oil Red O and immunostained for CD68, CD4 
and α SMA. Quantification of atherosclerotic lesion area (n = 16 mice/group) and of positive area for each cell type 
(n = 6 mice/group) is shown. Scale bars: 250 μ m. (E) mRNA expression of CD68 in aortic arch (n = 5 mice/group). 
Naïve C57BL/6 mice fed a normal chow diet were used as reference control. (F) Flow cytometric analysis of cell 
infiltrates isolated from aortic artery. The percentages of CD45+ leukocytes in whole cell isolates, and of CD11b+ 
monocytes and CD4+ lymphocytes in gated CD45+ cells, as well as, the number of CD45+, CD11b+ and CD4+ 
cells per aortic arch were determined. n = 8 mice per group, performed in two experiments. *p < 0.05, **p < 0.001, 
***p < 0.0001 vs. control.
www.nature.com/scientificreports/
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high-lipid diet showed many IFNγ -producing T cells, and a marginal presence of IL-17-producing CD4 cells 
(Fig. 4A), and high mRNA expression of IFNγ , and the inflammatory cytokine TNFα (Fig. 4B). Cardiac and aor-
tic DLNs of hyperlipidemic mice showed higher cellularity and percentages of CD4 cells and of T cells expressing 
IL-17 and IFNγ than aortic DLNs of naive C57Bl/6 mice fed a normal diet and than non-DLNs of atheroscle-
rotic mice (Fig. 4C, Supplementary Fig. S5A). In addition, spleens of apoE−/− mice with chronic atherosclerosis 
showed increased numbers of total and Th1 cells in comparison to spleens of naïve C57Bl/6 mice fed a normal 
diet (Supplementary Fig. S5). Treatment with cortistatin normalized the number and percentages of Th1 and 
Th17 cell populations in aortic DLNs and spleen (Fig. 4C, Supplementary Fig. S5). At the same time, apoE−/− 
mice treated with cortistatin showed elevated percentages of FoxP3+ Treg cells in DLNs at week 10, but not at 
week 16, in comparison to untreated mice (Fig. 4D). These findings support that downregulation of the athero-
genic T cell-mediated responses during the effector phase of the disease could play a role in the protective effect 
of cortistatin in atherosclerosis.
Figure 4. Cortistatin reduces the number of aortic and peripheral Th1 and Th17 cells in hyperlipidemic 
mice. ApoE−/− mice fed a high-fat diet were treated with PBS (control) or cortistatin (CST) three times per 
week starting one week after initiation of diet. (A) The presence of IL17- and IFNγ -producing T cells in aorta 
was determined by flow cytometric analysis of cells isolated from aortic arch 16 weeks after initiation of diet. 
n = 8 mice per group. (B) Cytokine levels were determined by qPCR in mRNA isolated from aortic arch 16 
weeks after initiation of diet. Naïve female C57Bl/6 (22 weeks old) mice fed a normal chow diet were used 
as reference. n = 5 mice/group. (C) Number and percentages of IFNγ -producing CD4 T cells and IL-17-
producing CD4 T cells in DLNs of aorta isolated 10 or 16 weeks after initiation of diet were determined by 
flow cytometric analysis. n = 8 mice/group. Plots correspond to intracellular cytokine staining in gated CD4+ 
cells. Supplementary Fig. S5 shows values of total cell numbers and percentages of CD4+, IFNγ + and IL-17+ 
cells in DLNs, spleen and non-draining mesenteric LN. (D) Percentage of CD25+FoxP3+ cells in gated CD4+ 
lymphocytes were determined by flow cytometry in DLNs of aorta isolated 10 or 16 weeks after initiation of 
diet. n = 8 mice per group. *p < 0.05; **p < 0.001; ***p < 0.0001 vs control.
www.nature.com/scientificreports/
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Cortistatin impairs the capacity of endothelial cells to bind immune cells. A crucial event in the 
atherogenic process is the binding of infiltrating cells with adhesion molecules expressed by activated endothelial 
cells of the plaque and their transmigration through the endothelial layer1. Therefore, we investigated the capacity 
of cortistatin to regulate these events by using different experimental approaches. We found that aortas obtained 
from cortistatin-treated atherosclerotic mice showed impaired capacity to bind macrophages and lymphocytes 
isolated from hyperlipidemic apoE−/− mice or even bone marrow-derived macrophages isolated from naïve 
C57Bl/6 mice (Fig. 5A). In agreement, aortas isolated from cortistatin-treated apoE−/− mice showed reduced 
expression of the adhesion molecules P-selectin, E-selectin and ICAM (Fig. 5B), suggesting that cortistatin could 
regulate the capacity of endothelial cells to bind immune cells. These results were partially confirmed using 
human vascular endothelial cells activated with oxidized low-density lipoprotein (oxLDL), a well-established 
in vitro atherosclerotic model of cell adhesion (Supplementary Fig. S6A and S6B). Moreover, in vitro treatment 
with cortistatin reduced the capacity of aortas obtained from atherosclerotic mice to recruit macrophages iso-
lated from apoE−/− or naïve C57Bl/6 mice (Fig. 5C, left panel). However, pretreatment of macrophages with 
cortistatin did not significantly affect their adhesion to atherosclerotic aortas (Fig. 5C, right panel). Similarly, 
treatment with cortistatin of mouse aortas activated with inflammatory stimuli reduced their capacity to bind 
Th1 cells (Fig. 5D). Again, the presence of cortistatin during the generation of DLN Th1 cells did not significantly 
affect their adhesion to activated aortas (Fig. 5D). Similarly, Th1 cells differentiated in the presence of cortistatin 
Figure 5. Cortistatin impairs binding of macrophages and lymphocytes to atherosclerotic aortas. 
(A) ApoE−/− mice fed a high-fat diet were treated with PBS (control) or cortistatin (CST) three times per week 
starting one week after initiation of diet. Aortas were isolated 12 weeks after initiation of diet and assayed for 
ex vivo cell adhesion of peritoneal macrophages (apoE−/− MΦ ) or DLN lymphocytes isolated from untreated 
atherosclerotic apoE−/− mice (at week 16) or of bone marrow-derived macrophages (BM-MΦ ) isolated from 
naïve C57Bl/6 mice. n = 5 mice/group, performed in duplicates. (B) Gene expression of adhesion molecules 
was determined by qPCR in the RNA samples isolated from aortas isolated from PBS-treated (control) or 
cortistatin-treated atherosclerotic apoE−/− mice 12 weeks after initiation of diet. Naïve C57Bl/6 mice fed a 
normal chow diet were used as reference. n = 5 mice/group. (C) Aortas isolated from untreated atherosclerotic 
apoE−/− mice 12 weeks after initiation of diet were ex vivo pretreated with medium (none) or cortistatin and 
then assayed for binding of peritoneal macrophages (apoE−/− MΦ ) isolated from untreated atherosclerotic 
apoE−/− mice (at week 16) or for binding of bone marrow-derived macrophages (BM-MΦ ) isolated from 
naïve C57Bl/6 mice (left panel). Similarly, apoE−/− MΦ or BM-MΦ were pretreated with medium (none) or 
with cortistatin before assaying their binding capacity to atherosclerotic aortas (right panel). (D) Th1 cells 
differentiated in the absence (untreated Th1) or presence of cortistatin (CST-treated Th1) were assayed for 
binding to aortas activated with inflammatory stimuli. Moreover, mouse aortas were preincubated with 
cortistatin (100 nM, grey column) before the addition of Th1 cells to culture. n = 3, in duplicates. *p < 0.05, 
**p < 0.001.
www.nature.com/scientificreports/
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did not change their binding capacity to P-selectin and E-selectin chimeras at the flow rate occurring in aortic 
arch (Supplementary Fig. S6C). Moreover, cortistatin showed no significant effect on the migratory capacity of 
macrophages in vivo and in vitro (Supplementary Fig. S6D and S6E). These findings suggest that cortistatin may 
impair the capacity of endothelial cells to recruit monocytes and atherogenic T cells into the plaque.
Cortistatin reduces the formation of foam cells by increasing the efflux of cholesterol. The 
accumulation of lipid-laden macrophage foam cells in the intima is an early event in the pathogenesis of athero-
sclerosis1–3. Infiltrating monocyte-derived macrophages ingest oxidized lipoproteins retained in subendothelial 
space of medium-large vessels. Lipoprotein uptake promotes the intracellular accumulation of various lipids, 
including cholesterol, in form of lipid droplets. This accumulation causes the macrophages to become foam cells 
and induces an inflammatory response. Therefore, we tested whether cortistatin regulated lipid accumulation in 
macrophages exposed to oxLDL. Cortistatin decreased the percentage of macrophages with mild and high load 
of lipid droplets (Fig. 6A). Cortistatin did not significantly affect the expression of CD36 and SRB1, two scavenger 
receptors involved in uptake of oxLDL by macrophages (Fig. 6B), arguing against this mechanism as one mainly 
involved in the effect of cortistatin on foam cell formation. However, cortistatin increased a 38% the efflux of cho-
lesterol to extracellular apolipoprotein AI (ApoAI) in oxLDL-activated macrophages (Fig. 6C). Because this effect 
depended on the presence of ApoAI in the culture, the membrane transporter ATP biding cassette A1 (ABCA1) 
emerged as a potential mediator of the effect of cortistatin in cholesterol efflux21. Indeed, cortistatin increased 
Figure 6. Cortistatin limits the formation of foam cells by promoting cholesterol efflux in macrophages. 
(A) Bone marrow-derived macrophages cultured in medium or stimulated with oxidized-LDL (oxLDL) in the 
absence or presence of cortistatin (CST, 100 nM) were stained with Oil Red O. The percentage of foam cells 
with mild (asterisk) and high (arrow head) content of lipid droplets was quantified by microscopy. Images are 
representative of four experiments performed in triplicate. (B) Expression of CD36, scavenger receptor-1 (SRB-
1), ABCA1 and PPARγ by macrophages exposed to oxLDL in the absence or presence of cortistatin analyzed 
by western blotting, normalized to GAPDH levels and expressed relative to oxLDL-treated cells (dashed 
horizontal line). n = 7 independent experiments. *p < 0.05, **p < 0.001 vs oxLDL-treated cells. (C) Efflux of 
[3H]-cholesterol by macrophages exposed to oxLDL in the absence or presence of cortistatin. n = 3 independent 
experiments, in duplicates. (D) Gene expression of ABCA1 and PPARγ in aortas isolated from PBS-treated 
(control) or cortistatin-treated (CST) atherosclerotic apoE−/− mice fed a high-fat diet during 16 weeks. n = 5 
mice/group. (E) Gene expression of CD206, CD163, PPARγ and TNFα by peritoneal macrophages isolated 
from PBS-treated (control) or cortistatin-treated (CST) atherosclerotic apoE−/− mice fed a high-fat diet during 
16 weeks. n = 5 mice/group. (F) Gene expression of CD206 in aortic arch isolated from PBS-treated (control) 
or cortistatin-treated (CST) atherosclerotic apoE−/− mice fed a high-fat diet during 16 weeks. n = 5 mice/group. 
*p < 0.05, **p < 0.001.
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the expression of ABCA1 in oxLDL-activated macrophages (Fig. 6B). In agreement, cortistatin also augmented 
the expression of peroxisome proliferator-activated receptor-γ (PPARγ ), an inducer of ABCA1 expression21, in 
oxLDL-activated macrophages (Fig. 6B). Noteworthy, we found that the expression of ABCA1 and PPARγ rela-
tive to the macrophagic marker CD68 was higher in aortas isolated from cortistatin-treated apoE−/− mice than 
in arteries isolated from untreated apoE−/− mice (Fig. 6D), suggesting that the effect observed for cortistatin in 
foam cells in vitro could be also exerted in vivo. Moreover, peritoneal macrophages isolated from atherosclerotic 
apoE−/− mice treated with cortistatin showed increased mRNA expression of PPARγ (Fig. 6E). Beside its role in 
ABCA1 induction, PPARγ is also involved in the expression of CD206, a marker of alternatively-activated M2 
macrophages, which play a protective effect in atherosclerosis22–25. Thus, we found that treatment with cortistatin 
increased the expression of CD206, and other M2 markers such as CD163, in peritoneal macrophages of athero-
sclerotic apoE−/− mice, at the same time that decreased the expression of TNFα , a marker of inflammatory mac-
rophages (Fig. 6E). Interestingly, aortas isolated from cortistatin-treated apoE−/− mice showed three-fold more 
expression of CD206 relative to CD68 than those isolated from untreated atherosclerotic mice (Fig. 6E), sug-
gesting that this neuropeptide favoured the presence of M2 macrophages in developing atherosclerotic plaques.
Discussion
Cortistatin is a neuropeptide that has recently emerged as a potent anti-inflammatory factor with capacity to 
regulate self-reactive responses in various experimental models of autoimmune disorders14,16–18. In this study, we 
provide evidence that cortistatin could be considered a protective therapy for cardiovascular disorders that course 
with exacerbated inflammatory and autoimmune responses, such as atherosclerosis. Using well-characterized 
mouse models of acute and chronic atherosclerosis, we demonstrate that cortistatin ameliorated plaque forma-
tion. Our data indicate that the effects of cortistatin are mainly exerted during the progression phase of the disease 
where innate and adaptive immune responses play pivotal roles. Whereas cortistatin did not significantly reduce 
the circulating levels of cholesterol in hyperlipidemic apoE−/− mice, it regulates various pathologic components 
of atherosclerosis, including T cell-driven inflammation against arterial wall, the formation of foam cells and 
the binding of immune cells to endothelial cells. Future work must address whether cortistatin is able to reduce 
plaque size in animals with established atherosclerotic lesions and whether it is more effective in animals in which 
high-fat diet is interrupted.
Numerous studies in human and animals models indicate that Th1 cells and IFNγ enhance development of 
atherosclerotic lesions and contribute to lesion rupture through various biological effects. These include induc-
tion of adhesion molecule and chemokine expression by endothelial cells, stimulation of secretion of proinflam-
matory cytokines, chemokines, reactive oxygen species and matrix metalloproteinases by macrophages and 
inhibition of cholesterol efflux from foam cells1,2,20,26–32. On the other hand, like Th1 cells, Th17 cells are present 
in human atherosclerotic plaques33,34, and the involvement of Th17 cells in the progression of atherosclerosis has 
been largely demonstrated in experimental models, especially during early steps35,36, although some controversy 
exists37.Treatment with cortistatin diminished the presence of Th1 and Th17 cells and their derived cytokines in 
arteries and aortic sinus bearing atherosclerotic plaques. This effect could be mainly mediated at peripheral level 
in lymphoid organs, because treatment with cortistatin diminished the number of Th1 and Th17 cells in lymph 
nodes that drain atherosclerotic carotid artery, heart and aortic arch. However, as discussed below, cortistatin 
would be also impairing the entry of Th1 cells into the plaque by regulating the capacity of endothelial cells to 
bind T cells and macrophages. Even once within arterial wall, atherogenic T cells could be locally deactivated by 
cortistatin. Whether cortistatin regulates activation and/or expansion of atherogenic T cell clones acting directly 
on T cells or indirectly on antigen presenting cells is still unknown. Previous studies support an action of corti-
statin on T cells and argues against any effect on dendritic cells5,14,16–18. Moreover, recent studies have associated 
the effect of cortistatin to the generation of Treg cells14,18. We also observed significant changes induced by cor-
tistatin in this cell population in arteries and DLNs of atherosclerotic mice, at least at early stages of the disease, 
promoting a beneficial Treg/Th1 balance. It has been demonstrated that peripheral activation/generation of Treg 
cells and their recruitment to atherosclerotic plaque limits the progression of the lesion in experimental models2,3.
Beside T cells, accumulation of foam cells in the intima layer is critical in the progression of atheromatous 
plaque1–3. We observed that cortistatin impaired the formation of foam cells in response to the atherogenic fac-
tor oxLDL in vitro. This could be also occurring in vivo, because cortistatin-treated animals showed reduced 
lipid-loaded macrophages in the atherosclerotic lesion area. This effect is mediated by an increase in the efflux of 
cholesterol from macrophages, but not by a decrease in oxLDL uptake, because cortistatin did not significantly 
affect the expression of scavenger receptors involved in the uptake of cholesterol. Previous studies identified cor-
tistatin as a potent regulator of macrophage function. Cortistatin regulates the secretion of a plethora of inflam-
matory mediators by activated macrophages, including inflammatory cytokines, chemokines and enzymes8,16–18. 
The present study is the first describing the action of cortistatin in the metabolism of cholesterol in macrophages. 
Although the precise molecular mechanisms involved in such effect remain unknown, our data indicate that 
cortistatin significantly increases the expression of the membrane transporter ABCA1 in macrophages, a pro-
tein critically involved in promoting cholesterol efflux from macrophages to extracellular acceptors21. Moreover, 
cortistatin up-regulates PPARγ , a transcription factor that up-regulates ABCA1 in macrophages21. Interestingly, 
both factors are increased in aortas isolated from cortistatin-treated atherosclerotic mice, supporting a link 
between these cholesterol efflux-inducing factors and the reduced numbers of aortic foam cells observed in ani-
mals treated with cortistatin. In agreement with these findings, it was previously reported that the stable ago-
nist of ghrelin-receptor hexarelin stimulated the metabolic cascade involving PPARγ -ABCA1 in monocytes and 
macrophages and ameliorated the formation of atherosclerotic plaques in apoE−/− mice38. Interestingly, many 
of the effects described for cortistatin in macrophages are mediated through its binding to ghrelin receptor5. 
Although further pharmacological studies are needed to identify specific receptors and signalling involved in 
the therapeutic action of cortistatin in atherosclerosis, previous reports suggested the capacity of cortistatin to 
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bind to two different types of receptors, i.e., ghrelin-receptor and somatostatin-receptors, supporting the higher 
therapeutic effect observed for cortistatin in comparison to somatostatin or ghrelin in autoimmune and inflam-
matory disorders, vascular remodelling or pain8,11,14–18,39. Noteworthy, despite their effects were not compared in 
the same study, cortistatin shows higher efficiency than hexarelin in ameliorating chronic atherosclerosis38. On 
the other hand, the induction of PPARγ in macrophages by cortistatin could be also related with their conversion 
to a M2-like phenotype, as we observed a correlation between increased expression of PPARγ and M2 markers 
in peritoneum and aortas of cortistatin-treated apoE−/− mice. This could have important therapeutic implica-
tions because various studies demonstrated the involvement of M2 macrophages in the inhibition atherosclerotic 
plaque progression22–25. In this sense, preliminary experiments from our laboratory support the capacity of corti-
statin to favor the generation of M2 macrophages in vitro (unpublished data).
On the other hand, various in vitro and in vivo experiments of this study indirectly suggest that cortistatin 
could regulate the entry of inflammatory monocytes and lymphocytes to the plaque by impairing their binding to 
arterial endothelium. This effect could be mediated by decreasing the expression of adhesion molecules, mainly 
P-selectin and E-selectin, in endothelial cells activated in an atherogenic environment. Evidence demonstrated 
that P-selectin and E-selectin together play an important role in both early and advanced stages of atheroscle-
rotic lesion development40,41. Moreover, macrophages and Th1 cells treated with cortistatin did not significantly 
change their capacity to bind to endothelial cells and to migrate to chemotactic stimuli, supporting that the effect 
of cortistatin is exerted at the endothelial level. Various studies indicate that endothelial cells express receptors for 
cortistatin and that they are able to respond to this neuropeptide42,43.
Finally, we recently reported that cortistatin limits proliferation and migration of SMCs in response to 
platelet-derived growth factor, which is produced by endothelial cells, macrophages and SMCs in the athero-
sclerotic plaque11. Moreover, cortistatin diminished the formation of neointimal lesions and prevented arterial 
stenosis in non-atherogenic conditions, but subjected to blood flow alteration and vascular injury11. The present 
study shows that treatment with cortistatin regulated the presence of SMCs in the plaque and intimal/medial ratio 
in carotid and aorta, suggesting that cortistatin could limit the outward vascular remodelling observed during 
the progression of atherosclerosis. However, it remains to determine whether this effect on SMCs could affect the 
stability of the mature plaque in advanced atherosclerosis.
An important question that needs to be addressed is which role is played by endogenous cortistatin in the 
regulation of atherosclerosis. Indirect evidence indicates that cortistatin must exert a protective role. Cortistatin 
is produced by arterial endothelium and SMCs and its expression increased in activated SMC cultures and in 
neointimal SMCs of arteries subjected to blood-flow alterations11. Moreover, cortistatin is expressed by human 
atheromas, specifically localized in SMCs and infiltrating macrophages11. Accordingly with its beneficial effect 
in vascular and immune disorders, animals lacking cortistatin responded with exacerbated neointima formation 
upon carotid ligation11, and macrophages and T cells isolated from cortistatin-deficient mice showed increased 
inflammatory and self-reactive responses18, supporting a role of cortistatin as an endogenous break of immune 
and vascular responses. Therefore, cortistatin-deficient mice should be more susceptible to suffer inflammatory 
vascular disorders. However, these animals showed an unexpected phenotype when subjected to various inflam-
matory and autoimmune disorders, such as sepsis, autoimmune encephalomyelitis or colitis, showing less inci-
dence and severity than wild-type mice18. This paradoxical effect is due to overproduction of glucocorticoid by a 
superactivated hypothalamus-pituitary-adrenal axis18, which makes complex evaluating the endogenous role of 
cortistatin in inflammatory cardiovascular disease.
In summary, we describe for the first time that, despite the unstability of cortistatin in body fluids (see 
Methods), this peptide could be highly efficient in the treatment of inflammatory cardiovascular disorders. Its 
multimodal action on various components of the disease would suppose a therapeutic advantage versus current 
treatments. Because the effects observed are based on mouse models of atherosclerosis, extrapolations to clinical 
practice have to be made with caution. Notably, injection of cortistatin has been proven safe (no side effects were 
observed) and effective in the treatment of patients with Cushing’s disease44. These findings encourage further 
studies aimed to assess whether cortistatin can be used as a pharmaceutical agent to prevent the clinical manifes-
tations of atherosclerosis in combination with therapies to lower plasma cholesterol.
Methods
Ethic statement. The experiments reported in this study followed the ethical guidelines for investigations 
of experimental animals approved by the Ethical Committee of Spanish Council of Scientific Research and per-
formed in accordance with the guidelines from Directive 2010/63/EU of the European Parliament on the protec-
tion of animals used for scientific purposes.
Experimental model of acute atherosclerosis. To induce acute atherosclerosis in hyperlipidemic mice, 
we subjected female C57Bl/6 apoE−/− mice (6 weeks-old, Charles River) to partial ligation of left carotid artery. 
Anesthesia was induced by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (80 mg/kg) mixture. 
A ventral midline incision (5 mm) was made in the neck and three of four caudal branches of left carotid artery 
(external carotid, internal carotid and occipital artery) were ligated with 6–0 silk suture, leaving the superior thy-
roid artery intact (Supplementary Fig. S1A). One day after surgery, animals were fed a high-fat Western diet (38% 
fat, 0.15% cholesterol, diet U8958, SAFE) and received intraperitoneally PBS (control) or mouse cortistatin-14 
(1 nmol, which corresponds to 1.7 μ g of cortistatin-14, obtained from American Peptides) every two days for 
a period of three weeks. The dose of cortistatin used in this study was selected in base of results obtained in 
previous experiments performed in other autoimmune and vascular models11,14–18. Serum levels of cortistatin 
elevated from 32 pg/ml (basal levels before injection) to 62 and 55 pg/ml at 10 min and 30 min after its intraperi-
toneal injection, respectively, and back to basal levels 1 hour later. When indicated, naïve female apoE−/− mice (9 
weeks-old) fed a normal chow diet were used as reference. Mice were sacrificed with carbon dioxide 14 or 21 days 
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after surgery. Some animals were subsequently perfused with cold-PBS and with 4% paraformaldehyde/0.1 M 
phosphate buffer pH 7.4 (buffered-PFA), and the ligated and contralateral unligated arteries were isolated for 
morphometry and immunofluorescence analysis. In other animals, ligated and unligated carotids were isolated 
for protein and gene expression determination, inflammatory infiltration analysis and ex vivo artery culture. 
Moreover, we isolated the ipsilateral and contralateral deep cervical lymph nodes (used as DLNs of carotid 
artery)45–48, spleen and mesenteric lymph nodes (used as non-DLN controls) for flow cytometric analysis. For 
morphometric and immunofluorescence analysis, we fixed the isolated carotid arteries in 4% buffered-PFA for 
6 hours, and then subjected them to cryopreservation in 30% sucrose/0.1 M phosphate buffer at 4 °C, embed-
ding in OCT-compound and freezing. We obtained a series of 20 cross cryosections (6 μ m thick) every 50 μ m 
over a 1 mm length of carotid artery beginning at 0.5 mm from carotid bifurcation. We measured the area occu-
pied by atherosclerotic lesion and by arterial medial layer in five carotid sections stained with hematoxylin/eosin 
(corresponding to divisions 1, 5, 9, 13 and 17 of the series) and in five carotid sections stained with Oil Red O 
(corresponding to divisions 3, 7, 11, 15 and 19 of the series) in a blinded manner using a Zeiss microscope and 
the ImageJ software. The mean for each of these 10 divisions (5 hematoxilyn/eosin- and 5 Oil-Red O-stained 
sections) was calculated for both arteries from every animal. Volume of the plaque on 1 mm length of carotid 
was calculated by the sum of plaque areas in each of these 10 divisions multiplied by 50 (50 is the length in μ m 
between divisions)49. Moreover, we analyzed the infiltration of inflammatory cells in the plaques in the other col-
lected 10 carotid cryosections by immunostaining with fluorescence-labelled antibodies against CD4, CD68 and 
α SMA as described below. Furthermore, to determine the number and phenotype of infiltrating cells in ligated 
and unligated carotid (isolated at day 21 post-ligation), a single-cell suspension was obtained by digestion of 
artery in a mixture of collagenases I and XI, DNase I and hyaluronidase (1 hour, 37 °C) as previously described50,51 
and then analyzed by flow cytometry as described below.
To determine the production of cytokines, segments of unligated and ligated carotid arteries isolated from 
untreated and cortistatin-treated atherosclerotic mice at day 21 were ex vivo cultured in complete DMEM 
(DMEM supplemented with 100 U/ml penicillin/streptomycin, 2 mM L-glutamine and 10% fetal calf serum) in 
the presence of phorbol 12-myristate 13-acetate (PMA, 25 ng/ml) plus ionomycin (0.5 μ g/ml) in 24-well plates at 
37 °C and 5% CO2. When indicated, cortistatin-14 (100 nM) was added to PMA/ionomycin-activated cultures of 
ligated carotid arteries isolated from untreated atherosclerotic mice at day 21. After 24 hours, we determined the 
cytokine contents in culture supernatants by using specific sandwich ELISAs (BD Pharmingen). Moreover, total 
proteins were obtained from ligated and unligated carotid arteries isolated from untreated and cortistatin-treated 
atherosclerotic mice at day 21 as previously described18, and the content of cytokines in protein extracts was 
determined by using specific sandwich ELISAs (BD Pharmingen).
Experimental model of chronic atherosclerosis. To induce chronic atherosclerosis, we fed female 
apoE−/− mice (6 weeks-old) with a high-fat Western diet and water ad libitum for 16 weeks. Animals received 
intraperitoneally PBS (control) or mouse cortistatin-14 (1 nmol) three times per week during 15 weeks starting 
one week after initiation of Western diet. We monitored plasma cholesterol (Accuntred Plus kit, Roche) and glu-
cose levels (One Touch Verio, LifeScan) every four weeks in blood samples collected from the tail, and measured 
body weight and food consumption every week. When indicated, naïve female C57Bl/6 mice (22 weeks-old) fed 
a normal chow diet were used as reference. Ten or 16 weeks after initiating a Western diet, mice were sacrificed 
with carbon dioxide and spleen, lymph nodes draining heart, aortic arch and aorta (deep cervical, cranial medi-
astinal, lumbar aortic and medial iliac lymph nodes)48 and mesenteric lymph nodes (used as non-DLN controls) 
were collected for flow cytometric analysis. In some animals, artery segments containing aortic sinus and aortic 
arch were dissected at week 16, and processed for determination of RNA expression or digested45,46 for flow 
cytometric characterization of inflammatory cell infiltration as described below. Moreover, the descending aorta 
comprising from proximal ascending thoracic aorta to iliac bifurcation was microdissected in situ at week 16 
and the atherosclerotic plaques were quantified after Sudan IV staining as described below. Some animals were 
sacrificed at week 16, perfused with cold-PBS and 4% buffered-PFA, and the segments containing heart-aortic 
sinus and aortic arch were isolated, fixed in 4% buffered-PFA for 6 hours, cryopreserved in sucrose, embedded in 
OCT-compound, cryosectioned and processed for morphometry and immunofluorescence analysis (see below). 
Furthermore, mice were anesthetized with isofluorane at weeks 10 and 16, and the peritoneal lavage was collected 
in cold-DMEM. Macrophages were isolated by plastic adherence of the peritoneal suspension by incubation dur-
ing 3 hours at 37 °C in complete DMEM and then used to quantify gene expression and for assaying cell adhesion 
and migration as described below.
Sudan IV and Oil Red O staining. Descending aorta was fixed in 4% buffered-PFA, depleted of adventitial 
fat and stained with 5% Sudan IV (dissolved in 50% acetone/35% ethanol) for 15 minutes, destained with 80% 
ethanol for 5 minutes, extensively washed in tap water during 1 hour, pinned flat onto a white rubber board, 
opened longitudinally using a dissecting microscope and photographed. Total aortic area and Sudan IV-positive 
lesion area were quantified in the images using ImageJ software.
Transversal and longitudinal cryosections (8 μ m thick) of aortic sinus and aortic arch were sequentially 
obtained and processed for hematoxylin/eosin staining or for Oil Red O staining. For Oil Red O staining, sec-
tions were rinsed with 60% isopropanol for 5 minutes, stained with 0.5% Oil Red O/60% isopropanol (20 °C, 
10 minutes), destained with 60% isopropanol for 2 minutes and extensively washed with distiller water. Finally, 
nuclei were counterstained with hematoxylin. Images of stained sections were acquired in a Zeiss microscope 
and the area occupied by the plaques in aortic arch and sinus was measured in a blinded fashion using the ImageJ 
software.
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Flow cytometric analysis. For analysis of artery-infiltrating cells, single-cell suspensions were isolated 21 
days after carotid ligation or 16 weeks after initiating a high-fat diet (see above) and were incubated with anti-
2.4 G2 antibody (Mouse BD Fc Block™ , 1:100, 4 °C, 10 minutes) to avoid non-specific binding to Fc-receptors 
and with 7-Aminoactinomycin D (Calbiochem, 1:100) to exclude dead cells. After washing in PBS/0.1% 
BSA, cells were surface stained with allophycocyanin-labelled anti-CD4, FITC-labelled anti-CD11b and 
phycoerythrin-labelled anti-CD45 monoclonal antibodies (each at 4–5 μ g/ml, BD Bioscience, 30 minutes, 4 °C) 
and were analyzed in a FACScalibur flow cytometer (BD Biosciences). Data were acquired until at least 100.000 
events were collected from a live gate using forward/side scatter plots and 7-Aminoactinomycin D staining.
To determine the number of cells expressing cytokines, infiltrating inflammatory cells isolated from ligated 
and unligated carotids at day 21 after ligation and from aortic sinus and aortic arch from apoE−/− mice at week 16 
after initiating a high-fat diet, as well as spleen, DLN and non-DLN cells isolated from apoE−/− mice at days 10 
and 21 after carotid ligation or at week 16 after initiating a high-fat diet were activated with PMA (25 ng/ml) for 
14 hours in the presence of monensin (1.33 μ M) for the last 6 hours. Cells were then incubated with anti-2.4 G2 
antibody plus 7-Aminoactinomycin D, washed in PBS/0.1% BSA and stained with allophycocyanin-labelled 
anti-CD4 monoclonal antibody as described above. After extensive washing, cells were fixed/permeabilized with 
Cytofix/Cytoperm solutions (BD Biosciences), stained with phycoerythrin-labelled anti-IL-17 and FITC-labelled 
anti-IFNγ monoclonal antibodies (BD Pharmingen, 2 μ g/ml, 30 minutes, 4 °C) and analyzed in a FACScalibur 
flow cytometer.
For FoxP3 staining, carotid cell isolates and DLN cells were isolated from mice 14 and 21 days after carotid 
ligation or 10 and 16 weeks after initiating a high-lipid diet and incubated with FITC-labelled anti-CD25 and 
allophycocyanin-labelled anti-CD4 monoclonal antibodies (5 μ g/ml, BD Biosciences) for 1 hour at 4 °C. After 
extensive washing, cells were fixed/permeabilized (eBioscience), stained with phycoerythrin-labeled anti-FoxP3 
antibody (5 μ g/ml, eBioscience) for 30 minutes at 4 °C and analyzed in a FACScalibur flow cytometer. In all cases, 
we used isotype-matched antibodies (BD Biosciences) as controls.
Determination of lipid accumulation and cholesterol efflux in macrophages. Macrophages were 
generated by differentiating bone marrow cell precursors isolated from untreated C57Bl/6 mice (sacrificed by 
carbon dioxide) and then incubated in complete DMEM in the presence of macrophage-colony stimulating factor 
(Preprotec, 20 ng/ml) for 6–8 days. To determine the accumulation of lipid droplets, macrophages (5 × 105) were 
seeded in coverslips (8 hours, 37 °C, in complete DMEM) and incubated in DMEM supplemented with 100 U/ml 
penicillin/streptomycin, 2 mM L-glutamine and 2% fetal calf serum in the presence of oxLDL (50 μ g/ml, KALEN 
Biomedical) and mouse cortistatin-14 (100 nM). After 24 hours, cells were fixed in 4% buffered-PFA (10 min-
utes, 22 °C) and intracellular neutral lipids were stained with Oil Red O (0.15%, 15 minutes, 22 °C). After exten-
sive washing in water, macrophages were counterstained with hematoxylin and observed in a Zeiss microscope. 
Images were analyzed with the ImageJ software to quantify the content of intracellular lipid droplets per cell and 
determine the percentage of foam cells.
To determine the cholesterol efflux, macrophages (105) were cultured in 96-well plates with complete DMEM. After 
16 hours, cells were incubated in DMEM-BSA (DMEM supplemented with 100 U/ml penicillin/streptomycin, 2 mM 
L-glutamine and 0.2% fatty acid-free bovine serum albumin) in the presence of oxLDL (50 μ g/ml), [3H]-cholesterol 
(0.5 μ Ci/ml, PerkinElmer) with or without mouse cortistatin-14 (100 nM) for 10 hours. Cells were then washed with 
DMEM-BSA and incubated again with ApoAI (10 μ g/ml, Sigma) with or without cortistatin (100 nM). After 10 hours, 
culture supernatants were collected and cells lysed in NaOH (0.1 M, 5 hours, 22 °C). The cpm in cell lysates (lys) and 
supernatants (sup) were quantified in a MicroBeta Trilux counter, and the ApoAI-mediated efflux of cholesterol was 
determined by using the following formula: % efflux = (cpm sup/cpm sup + lys) × 100.
Immunofluorescence analysis. Sections of carotids, aortic sinus and aortic arch were fixed in 4% 
buffered-PFA (10 minutes, 20 °C), blocked with 10% goat serum/0.2% Triton X-100/1% BSA (45 minutes, 20 °C) 
and incubated with rabbit anti-mouse CD68 antibody (BD Bioscience, dilution 1:500) or rat anti-mouse CD4 
antibody (BD Bioscience, dilution 1:1000) and mouse anti-mouse α SMA antibody (Sigma, dilution 1:1000) over-
night at 4 °C. After extensive washing with PBS/1% BSA, sections were incubated with Alexa Fluor 546-conjugated 
goat anti-rabbit antibody, Alexa Fluor 488-conjugated goat anti-rat antibody, Alexa Fluor 488-conjugated goat 
anti-mouse antibody, or Alexa Fluor 594-conjugated goat anti-mouse antibody (Life Biotechnology, 1 hour, 20 °C, 
all diluted at 1:1000 in PBS/2% goat serum/0.1% Triton X-100). Nuclei were Hoechst-counterstained and slices 
examined in an Olympus fluorescence microscope. Sections in which we omitted primary antibodies were used as 
negative controls. We quantified the area occupied by florescence-stained cells in the plaque of arteries and aortic 
sinus using the ImageJ software.
Determination of gene expression by real-time PCR. Total RNA was isolated from carotid arteries, 
aortas and peritoneal macrophages following the manufacturer’s protocol (Tripure, Roche). Precipitated RNA was 
treated with DNase 1 (Sigma-Aldrich) before reverse transcription (RevertAid First Strand cDNA Synthesis Kit, 
Thermo Fisher Scientific). SYBER green quantitative PCR (SensiFast Sybr No-Rox mix, Bioline) was performed 
on the Bio-Rad CFX using the following conditions: 95 °C for 5 minutes followed by 35 cycles at 95 °C for 30 
seconds, annealing (see Supplementary Table S1 for annealing temperature and time used for each gene) and 
extension at 72 °C for 30 seconds. Primer sequences are listed in Supplementary Table S1. The expression of each 
gene was normalized against the expression of the housekeeping gene GAPDH in every PCR reaction.
Western blot analysis. Mouse macrophages differentiated from bone marrow were cultured in complete 
DMEM in the absence or presence of oxLDL (50 μ g/ml) and mouse cortistatin-14 (100 nM). After 16 hours, cells 
were lysed by incubation with lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 
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1% sodium deoxycholic acid, 0.1% SDS and 10 μ g/ml of a cocktail of proteinase inhibitors) for 30 minutes on ice. 
Proteins extracts (20 μ g/lane) were separated on 7.5% SDS-polyacrylamide gels and blotted onto polyvinylidene 
difluoride membranes (Millipore) using a semidry system. Membranes were blocked with TBS-Tween-20/5% 
non-fat dry milk for 1 hour at room temperature and subsequently probed overnight at 4 °C with primary 
rabbit anti-mouse CD36 or ABCA-1 antibodies (at 1/1000; Novus Biologicals), rabbit anti-mouse PPARγ or 
SRB1 antibodies (at 1/500, Cell Signaling) or rabbit anti-mouse GAPDH antibody (at 1/5000, R&D System). 
Immunodetection was performed by incubation with a peroxidase-conjugated anti-rabbit antibody (at 1:5000, 
2 hours, 20 °C, Dako-Cytomation) and developed with enhanced chemiluminescence detection system (ECL plus, 
Amersham). Protein expression was represented as % of expression in densitometry units relative to GAPDH.
Adhesion assay of macrophages, lymphocytes and Th1 cells to whole aorta. The macrophage and 
lymphocyte adhesion assay was performed as previously described35. Aortas from untreated and cortistatin-treated 
ApoE−/− mice fed a high-fat diet for 10 weeks were dissected out, opened longitudinally and pinned to a sterile 
agarose gel in serum-free DMEM. In parallel, peritoneal macrophages and DLN lymphocytes were isolated from 
ApoE−/− mice after 16 weeks with Western diet, and macrophages were differentiated from bone marrow cell pre-
cursors of C57Bl/6 mice (see above). Peritoneal macrophages, bone marrow-derived macrophages and DLN lym-
phocytes were labelled with calcein-AM (10 μ M, Molecular Probes) following manufacturer’s recommendations. 
Calcein-labelled cells (106 cells) were co-incubated with pinned aortas in complete DMEM for 1 hour at 37 °C. 
Nonadhered cells were washed off with PBS and the number of cells firmly adhered to the aorta were counted in 
three consistent fields using a fluorescent microscope (Zeiss AxioObserver Z1). The areas counted were identified 
within a 100 mm2 grid, and the same locations per aorta were counted by a blinded observer. In some experiments, 
aortas isolated from apoE−/− mice fed a high-fat diet for 10 weeks were pretreated with cortistatin (100 nM) for 12 
hours in complete DMEM at 37 °C before the addition of macrophages. Alternatively, macrophages were preincu-
bated with cortistatin (100 nM) in complete DMEM for 6 hours before their addition to pinned aortas.
Furthermore, CD4+ cells (106/ml) isolated from spleen of C57Bl/6 mice (sacrificed by carbon dioxide) by 
immunomagnetic negative selection (Invitrogen) were differentiated to Th1 cells (purity > 94% IFNγ + cells) by 
stimulation during 5 days with anti-CD3/anti-CD28 antibodies (5 μ g/ml, BD Pharmingen) in the presence of IL-2 
(25 U/ml, PreproTech), IL-12 (20 ng/ml, PreproTech) and anti-IL4 antibody (5 μ g/ml, BD Pharmingen), as previ-
ously described52. Cortistatin (100 nM) was added to Th1 cells at days 0 and 3 of culture. Th1 cells differentiated 
in the absence or presence of cortistatin were Hoechst-stained and added to aorta arteries from C57Bl/6 mice (8 
weeks-old) that were previously opened longitudinally, pinned in sterile agar and activated during 6 hours with 
IL-1β (20 ng/ml) and TNFα (100 ng/ml) in complete RPMI medium. After 45 minutes of incubation at 37 °C and 
5% CO2, aortas were extensively washed with PBS and scanned by spinning disk microscopy (Olympus). The total 
number of Th1 cells bound to aorta was determined by analysis of consecutive deconvolved images of the whole 
aorta using Methamorph software.
Binding assay to adhesion molecule chimeras. Th1 cells differentiated in the absence or presence of 
cortistatin (see above) were diluted at 5 × 105 cells/ml in PBS containing 0.1% BSA and 20 mM HEPES pH 7.4 and 
perfused over P-selectin or E-selectin chimera-coated coverslips (5 μ g/ml, R&D Systems) in parallel plate flow 
chambers (Harvard Apparatus). We applied a laminar flow rate of 1 dynes/cm2 (a share that corresponds to aortic 
arch). We recorded during one minute the number of Th1 cell interactions with selectin chimeras with a phase 
contrast objective (20x)and a microscope connected to Videolab software (Ed Marcus Laboratories).
Determination of binding of monocytes to endothelial cells. Human umbilical vein endothelial cells 
(HUVECs, Clonetics) were cultured (105 cells/well, in 48-well plates) in complete EGM-2 medium (Clonetics) 
containing 20% FBS in the presence of oxLDL (50 μ g/ml) and/or various concentrations of human cortistatin-14 
for 24 hours. Moreover, HUVEC monolayers were extensively washed with EGM-2 medium and co-incubated 
with 104 calcein AM-labelled THP1 human monocytic cells (ATCC) for 1 hour. After extensive washing, the 
number of THP1 cells bound to HUVEC monolayer was determined in a fluorescence microscope.
Determination of macrophage migration. Macrophage migration was measured using a modified 
Boyden’s chamber method. Macrophages from untreated or cortistatin-treated ApoE−/− mice were isolated 
from peritoneal lavage after 16 weeks on a high-fat diet, suspended in complete DMEM medium and plated 
on Matrigel-coated 8 μ m cell culture inserts (Millipore) at 5 × 104 cells per insert. MCP-1 was added to a final 
concentration of 50 ng/ml to the lower chamber and the cells were incubated for 8 hours at 37 °C. Alternatively, 
macrophages isolated from untreated ApoE−/− mice were isolated from peritoneal lavage after 16 weeks on a 
high-lipid diet and incubated with DMEM medium in the absence or presence of cortistatin (100 nM) in the 
upper insert 20 minutes before the addition of MCP-1 in the lower chamber. The inserts were then lifted, 
non-migrated cells on the upper surface of the membrane were removed with a cotton swab and the membrane 
was then fixed in methanol and stained with DAPI. The DAPI-positive cells on the lower surface of the membrane 
were counted under an inverted fluorescence microscope (Olympus) and the cell migration was expressed as the 
number of cells per field of view.
Statistical analysis. All data are mean ± s.e.m. We analyzed data for statistical differences using Student’s 
t-test or one-way ANOVA followed by a test for multiple comparisons or with non-parametric Mann–Whitney U 
test for comparisons between two groups. We considered P-values < 0.05 (two-tailed) as significant.
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